高级搜索

调强放疗联合单药顺铂不同化疗方案同期治疗鼻咽癌的急性不良反应比较

程金建, 杨华, 卢志平, 陆合明, 黄翌航, 莫颖, 陈甲信

程金建, 杨华, 卢志平, 陆合明, 黄翌航, 莫颖, 陈甲信. 调强放疗联合单药顺铂不同化疗方案同期治疗鼻咽癌的急性不良反应比较[J]. 肿瘤防治研究, 2015, 42(03): 285-289. DOI: 10.3971/j.issn.1000-8578.2015.03.016
引用本文: 程金建, 杨华, 卢志平, 陆合明, 黄翌航, 莫颖, 陈甲信. 调强放疗联合单药顺铂不同化疗方案同期治疗鼻咽癌的急性不良反应比较[J]. 肿瘤防治研究, 2015, 42(03): 285-289. DOI: 10.3971/j.issn.1000-8578.2015.03.016
shu
CHENG Jinjian, YANG Hua, LU Zhiping, LU Heming, HUANG Yihang, MO Ying, CHEN Jiaxin. Comparison of Acute Toxicity between Intensity-modulated Radiotherapy with Cisplatin Alone Concurrent Chemotherapy Weekly and Every Three Weeks for Nasopharyngeal Carcinoma Patients[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 285-289. DOI: 10.3971/j.issn.1000-8578.2015.03.016
Citation: CHENG Jinjian, YANG Hua, LU Zhiping, LU Heming, HUANG Yihang, MO Ying, CHEN Jiaxin. Comparison of Acute Toxicity between Intensity-modulated Radiotherapy with Cisplatin Alone Concurrent Chemotherapy Weekly and Every Three Weeks for Nasopharyngeal Carcinoma Patients[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 285-289. DOI: 10.3971/j.issn.1000-8578.2015.03.016
shu

调强放疗联合单药顺铂不同化疗方案同期治疗鼻咽癌的急性不良反应比较

  • 1. 530021 南宁，广西壮族自治区人民医院肿瘤中心放疗科；2. 530021 南宁，广西医科大学药学院

基金项目: 国家自然科学基金（ 81160284）
详细信息
    作者简介:

    程金建（1978-），男，硕士，主治医师，主要从事恶性肿瘤放疗基础及临床研究

    通讯作者:

    陈甲信，E-mail：cjx166@aliyun.com

  • 中图分类号: R730.58; R739.63

Comparison of Acute Toxicity between Intensity-modulated Radiotherapy with Cisplatin Alone Concurrent Chemotherapy Weekly and Every Three Weeks for Nasopharyngeal Carcinoma Patients

  • 1. Department of Radiation Oncology, Cancer Center, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China; 2. School of Pharmaceutical Sciences, Guangxi Medical University, Nanning 530021, China

摘要

    摘要
  • 摘要: 目的 比较无远处转移鼻咽癌（nasopharyngeal carcinoma, NPC）调强放疗（intensity-modulated radiotherapy，IMRT）联合单药顺铂每周（40mg/m2，1次/周）和每3周（80~100mg/m2，1次/3周）同期放化疗的急性不良反应和治疗前后的营养状况差异。方法 回顾分析45例IMRT联合单药顺铂同期化疗的非转移NPC患者临床资料，急性不良反应评估采用CTCAE 3.0标准，不良反应和营养状况统计分析采用t检验、卡方分析或精确概率法以及方差分析检验。结果 45例患者口干、咽痛、口腔黏膜炎、皮炎、恶心、呕吐及骨髓抑制3~4级不良反应发生率分别为6.7%、15.6%、28.9%、6.7%、8.9%、13.3%和22.2%。治疗后BW、BMI、TP、BUN、Cr、Na+、K+、Ca2+和Cl-变化的性别分层方差分析差异均无统计学意义（P＞0.05），ALB变化接近统计学意义。组内分析显示两组治疗后ALB、TP、Na+和Cl-均下降（P＜0.05），但顺铂每周组BW、BMI下降更明显（P＜0.05）。结论 治疗前后两组营养状况均有不同程度下降，顺铂每周组营养失衡较顺铂每3周组更普遍，但治疗前后两组变化无明显差异。

     

    Abstract: Objective To compare the acute toxicities and nutritional status between non-metastasis nasopharyngeal carcinoma(NPC) patients treated by intensity-modulated radiotherapy(IMRT) combined with 40 mg/m² cisplatin alone concurrent chemotherapy weekly and those treated by IMRT with 80-100 mg/m2 cisplatin every three weeks. Methods A retrospective clinical data analysis was conducted on 45 patients with non-metastatic NPC. Patients received 40 mg/m² cisplatin weekly or 80-100 mg/m2 cisplatin every three weeks, concurrently with IMRT. The National Cancer Institute Common Toxicity Criteria version 3.0 scale (CTCAE V3.0) was used to assess the chemotherapy and acute toxicities. The acute toxicities and nutritional status were analyzed statistically by t-test, Chi-Square test/Chi-Square Goodness-of-Fit test or Analysis of Variance (ANOVA). Results In 45 NPC patients treated by IMRT, 31 patients received 40 mg/m² cisplatin weekly and 14 patients received 80-100 mg/m2 cisplatin every three weeks concurrently chemotherapy. The grade 3-4 acute toxicity occurrence rates of xerostomia, pharyngodynia, oral mucositis, dermatitis, nausea, vomit and myelosuppression were 6.7%, 15.6%, 28.9%, 6.7%, 8.9%, 13.3% and 22.2%, respectively. Although the changes of BW, BMI, ALB, TP, BUN, Cr, Na+, K+, Ca2+ and Cl- had no statistical difference between two groups after treatment(P＞0.05) by Gender stratification ANOVA, the change of ALB was closed to a statistical difference. Both groups of ALB, TP, Na+ and Cl- were decreased after treatment (P＜0.05), but BW and BMI in cisplatin weekly group were decreased more severely than those in cisplatin every three weeks group. Conclusion It seems that the nutritional status of cisplatin weekly group is decreased more generally than that of cisplatin every three weeks group, but without significant difference in two groups before and after treatment.

     

    • HTML全文
    • 参考文献(24)
  • [1] Liu XQ, Luo W, Tang YQ, et al. A matched cohort analysis of three-dimensional conformal radiotherapy versus conventional radiotherapy for primary nasopharyngeal carcinoma[J]. Ai Zheng, 20 08, 27(6): 606-11.[刘晓清, 罗伟, 汤轶强, 等. 三维适形与常规 二维放射治疗初治鼻咽癌的配对设计队列研究[J]. 癌症, 2008, 27 (6): 606-11.]
    [2] Fang FM, Chien CY, Tsai WL, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study[J]. Int J Radiat Oncol Biol Phys, 20 08, 72(2): 356-64.
    [3] Fang FM, Tsai WL, Chen HC, et al. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques[J]. Cancer, 2007, 109(2): 313-21.
    [4] Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?[J]. Int J Radiat Oncol Biol Phys, 2011, 80(3): 661-8.
    [5] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: head and neck cancers,V.2.2013[s]. http:// www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed March 8, 2014.
    [6] Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial[J]. Lancet Oncol, 2012, 13(2): 163-71.
    [7] Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase Ⅱ study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation[J]. Ann Oncol, 2012, 23(2): 427-35.
    [8] Xu L, Pan J, Wu J, Pan C, et al. Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break[J]. Radiother Oncol, 2010, 96(1): 94-9.
    [9] Sun X, Su S, Chen C, et al. Long-term outcomes of intensitymodulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities[J]. Radiother Oncol, 2014, 110(3): 398-403.
    [10] Lee AW, Tung SY, Ngan RK, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials[J]. Eur J Cancer, 2011, 47(5): 65 6-66.
    [11] Loong HH, Ma BB, Leung SF, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3): 30 0-4.
    [12] Chen QY, Wen YF, Guo L, et al. Concurrent chemoradiotherapy vs. radiotherapy alone in stage Ⅱ nasopharyngeal carcinoma: phase Ⅲ randomized trial[J]. J Natl Cancer Inst, 2011, 103(23): 17 61-70.
    [13] Lee AW, Tung SY, Chan AT, et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2006, 66(1): 142-51.
    [14] Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China[J]. Int J Radiat Oncol Biol Phys, 2008, 71(5): 1356-64.
    [15] Ohno T, Thinh DH, Kato S, et al. Radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for N2-3 nasopharyngeal cancer: a multicenter trial of the Forum for Nuclear Cooperation in Asia[J]. J Radiat Res, 2013, 54(3): 46 7-73.
    [16] Liu H, Chen QY, Guo L, et al. Feasibility and efficacy of chemoradiotherapy for elderly patients with locoregionally advanced nasopharyngeal carcinoma: results from a matched cohort analysis[J]. Radiat Oncol, 2013, 8: 70.
    [17] Zhang AM, Fan Y, Wang XX, et al. Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy [J] Radiother Oncol, 2012, 104(3): 279-85.
    [18] Lu H, Chen J, Huang B, et al. Feasibility and efficacy study of weekly cisplatin with concurrent intensity-modulated radiation therapy for nasopharyngeal carcinoma: preliminary results[J]. Oral Oncol, 2010, 46(10): 743-7.
    [19] Ng K, Leung SF, Johnson PJ, et al. Nutritional consequences of radiotherapy in nasopharynx cancer patients[J]. Nutr Cancer, 20 04, 49(2): 156-61.
    [20] Oates JE, Clark JR, Read J, et al. Prospective evaluation of quality of life and nutrition before and after treatment for nasopharyngeal carcinoma[J]. Arch Otolaryngol Head Neck Surg, 2007, 133(6): 53 3-40.
    [21] Cheng JJ, Yang H, Chen JX, et al. The impacts of intensitymodulated radiotherapy and chemotherapy on nutritional status of patients with nasopharyngeal carcinoma[J]. Guangdong Yi Xue, 20 11, 32(17): 2336-8. [程金建, 杨华, 陈甲信, 等. 调强放疗及化 疗对鼻咽癌患者营养状况的影响[J]. 广东医学, 2011, 32(17): 23 36-8.]
    [22] Cheng JJ, Yang H, Lu HM, et al. Analysis of body weight loss and influence factors during intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma[J]. Zhong Liu Fang Zhi Yan Jiu, 2013, 40(8): 767-71. [程金建, 杨华, 陆合明, 等. 鼻咽癌 患者调强放疗过程中体重变化及影响因素分析[J]. 肿瘤防治研 究, 2013, 40(8): 767-71.]
    [23] Wang X, Lu J, Xiong X, et al. Anatomic and dosimetric changes during the treatment course of intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma[J]. Med Dosim, 20 10, 35(2): 151-7.
    [24] Wang W, Yang H, Hu W, et al. Clinical study of the necessity of replanning before the 25th fraction during the course of intensitymodulated radiotherapy for patients with nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2010, 77(2): 617-21.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1301
  • HTML全文浏览量:  331
  • PDF下载量:  425
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-03-20
  • 修回日期:  2014-10-09
  • 刊出日期:  2015-03-24

目录

摘要
HTML全文
    参考文献(24)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11970178 今日访问：6481

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭